US Patent

US11065198 — Dispersible compositions

Formulation · Assigned to Janssen Sciences Ireland ULC · Expires 2037-10-23 · 11y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects dispersible compositions containing rilpivirine or a pharmaceutically acceptable acid addition salt thereof for treating HIV infection.

USPTO Abstract

The present invention is concerned with dispersible compositions comprising rilpivirine or a pharmaceutically acceptable acid addition salt thereof as an active ingredient. Such compositions are useful in the treatment of HIV infection and their dispersibility properties lend themselves to be useful in particular amongst the pediatric or geriatric population.

Drugs covered by this patent

rilpivirine-hydrochloride (RILPIVIRINE HYDROCHLORIDE)

Patent Metadata

Patent number: US11065198
Jurisdiction: US
Classification: Formulation
Expires: 2037-10-23
Drug substance claim: No
Drug product claim: Yes
Assignee: Janssen Sciences Ireland ULC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.